GSK

News

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.

News

GSK ends decades-long hiatus in oral antibiotics for UTIs

The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.

News

GSK taps into UK health data for dementia study

GSK joins with two UK research organisations to explore a possible link between its shingles vaccine Shingrix and a reduced risk of dementia.

News

GSK bows to Trump pressure and pauses diversity policies

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Trump.

News

FDA sets June date for Gilead's twice-yearly HIV PrEP

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

News

Vaccines production line at GSK facility in Wavre, Belgium

GSK gets ready for its next big vaccine launch

GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

GSK makes fresh neuroscience foray with £2bn+ ABL deal

GSK ends decades-long hiatus in oral antibiotics for UTIs

GSK taps into UK health data for dementia study

GSK bows to Trump pressure and pauses diversity policies

FDA sets June date for Gilead's twice-yearly HIV PrEP

GSK gets ready for its next big vaccine launch

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks